{"id":533749,"date":"2021-09-02T08:04:06","date_gmt":"2021-09-02T12:04:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/"},"modified":"2021-09-02T08:04:06","modified_gmt":"2021-09-02T12:04:06","slug":"ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/","title":{"rendered":"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">REHOVOT, Israel and WILMINGTON, Del., Sept.  02, 2021  (GLOBE NEWSWIRE) &#8212; Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in two upcoming virtual investor conferences in September:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">H.C. Wainwright 23<sup>rd<\/sup> Annual Global Investor Conference: Corporate Presentation available on-demand starting Monday, September 13, 2021 at 7:00 am ET.<\/li>\n<li style=\"margin-bottom:8pt\">Citi\u2019s 16th Annual Biopharma Virtual Conference: Management will participate in investor meetings on Thursday, September 9, 2021.<\/li>\n<\/ul>\n<p>A webcast of the H.C. Wainwright 23<sup>rd<\/sup> Annual Global Investor Conference presentation may be accessed by visiting the Events &amp; Presentations section of Ayala\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8iOyCayWyseP2ghMifu0qc5x8rqAfVqWaeKD7_3cVrEvZ4ydZz8Jfki85e52NiMAm2qwj-Y707MBWJ8WNfYR9sfdNu611ntBiu8Jy1kmggM=\" rel=\"nofollow noopener\" target=\"_blank\">ir.ayalapharma.com<\/a>. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.<\/p>\n<p>\n        <strong>About Ayala Pharmaceuticals<\/strong>\n      <\/p>\n<p>Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala\u2019s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CEm8_YM_bDNDjT7bvuxEeN5czfFPlEauVTFu2Hd78LgtXPrMvOlAz5xhWHZrnG5Q02-Sqdh9243WnFhfbxc9I_-RksIzLgKwC4gXTlYPqadiJFO545zh72KxsUa-clX8NJVtNNd67XGSxcvrKYGtUJUEBpfwM--Bj8xRKQijus7TZrl74vbZ4o-xNk1xbY7BeJV34KlKNwfV4FrvCU_jbekd3bbU0vQR5a4NK9zOsinwL0LWJirbWOyP25mkIAEVIrhP0cXV1IGFqRFSe4yDf4OwG2vQxniSk7vVITTxMvVhWupWlPmJVCEyS2DFw3aYb1eExi_9bRhEagYf5szNqGRLB41gSh6fCwsuD3KXzN6vO4gEqN4-_XmGUCqHmSDyhxzElyA1CvFebWt6LRQG9I1YIh514sjE71vFH0l-Z94rZ7QobzrEgDYZDlh6Igc0\" rel=\"nofollow noopener\" target=\"_blank\"><u>ACCURACY<\/u><\/a>) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aaTQMlwotPIXLZ50jzbrLyB7D0VFNrLsLnj6CUp0OHcbsmQBlxk_I4s_N5HsLNpQM3xRSBuV41K66l5wGRT-j86guvoghhpyXdYvx6P7cvFnInSJn7RBpbTIpPbZkvdVsA6QwFdWUpZsivC9lAwtP00oBoK9t97RXfr-XeCAGdSyrSU8tmfah7_R2K_DYsnsUlF50939emBMvt5rCHhcgF2AmFqr6ot8-6qyp2YgEqeiG1qVjG3yUyGVz28u4iMDm1FEB9su0oHMkSI23l0QhO4QTv_JHLzJrI_KFRpKYySeoY2TyeX_uKvZD3Kv21jidbhMv67Cj_agINWnZoVgmAY1K_R5p2yMvMaMMMee6vB6mPxC99m_LN_sgytidhRyeNcfRnQEsUd1NBgwUsa6LK20F4O-rxvKdKVhnKdD0ciVdu7p71zhmP54qIDpzxGh5nP3pIQn1CuL3WyJVRwh8G6QLrUwzh_2kNQO7GWPUCd7XPe3__M3fPB-u1Y8WoZxhfITY9vgfT11R8RckZXWFw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>TENACITY<\/u><\/a>) bearing Notch activating mutations and other gene rearrangements. AL102 is currently in a Pivotal Phase 2\/3 clinical trials for patients with desmoid tumors (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LFetmP0X82GGp2wll4gilqjpuRf3lkAYY_vDIhsOnG3aNDE0f2G1R9vuHM3NVATXztPoXLYE2Zwno6AYNv9aSz6XIrOqL43l7W509t9kL20=\" rel=\"nofollow noopener\" target=\"_blank\"><u>RINGSIDE<\/u><\/a>) and is being evaluated in a Phase 1 clinical trial in combination with Novartis\u2019 BMCA targeting agent, WVT078, in Patients with relapsed\/refractory Multiple Myeloma. For more information,\u00a0visit\u00a0<u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rVASjCXa9LzQasSjIuW5JjcwhKaKVexx5RllB3ohtfjDOYqRYpnsHuiucETPPlnA2cB6HEdpnh_n4qQALMg9ArVEo80V5eC-mj6v1swCnN4=\" rel=\"nofollow noopener\" target=\"_blank\">www.ayalapharma.com<\/a><\/u>.<\/p>\n<p>\n        <strong>Investors: <\/strong><br \/>\n        <br \/>Julie Seidel <br \/>Stern Investor Relations, Inc. <br \/>+1-212-362-1200 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZF42WQ3QnaaOV-2gwSwULNNzYwgofFNQ7-khw1vKinJfi5cj_SX4s7FsagWL8TmfuJaVD4TVe4m0kt_8JTPrfeSmYbkkHfTJHW6zYY3s93Y=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Julie.seidel@sternir.com<\/u><\/a><\/p>\n<p>\n        <strong>Ayala Pharmaceuticals: <\/strong><br \/>\n        <br \/>+1-857-444-0553 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0Ve0at_O83-CusGjb_Vhp397FAJDqSVzHP-yCpixgDVdusvU20Q7k9X9wfBiv5vqJnTls79foKZCtTV9GK679Bal2B10Y3A11ysw4-Tn8KE=\" rel=\"nofollow noopener\" target=\"_blank\"><u>info@ayalapharma.com<\/u><\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YjI2OGVjZjEtMzVjMi00MzNiLWJiYTQtNDhjMDUzZTAyYzk1LTEyMDY1NjU=\/tiny\/Ayala-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in two upcoming virtual investor conferences in September: H.C. Wainwright 23rd Annual Global Investor Conference: Corporate Presentation available on-demand starting Monday, September 13, 2021 at 7:00 am ET. Citi\u2019s 16th Annual Biopharma Virtual Conference: Management will participate in investor meetings on Thursday, September 9, 2021. A webcast of the H.C. Wainwright 23rd Annual Global Investor Conference presentation may be accessed by visiting the Events &amp; Presentations section of Ayala\u2019s website at ir.ayalapharma.com. An archived replay of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-533749","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in two upcoming virtual investor conferences in September: H.C. Wainwright 23rd Annual Global Investor Conference: Corporate Presentation available on-demand starting Monday, September 13, 2021 at 7:00 am ET. Citi\u2019s 16th Annual Biopharma Virtual Conference: Management will participate in investor meetings on Thursday, September 9, 2021. A webcast of the H.C. Wainwright 23rd Annual Global Investor Conference presentation may be accessed by visiting the Events &amp; Presentations section of Ayala\u2019s website at ir.ayalapharma.com. An archived replay of the &hellip; Continue reading &quot;Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T12:04:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences\",\"datePublished\":\"2021-09-02T12:04:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/\"},\"wordCount\":378,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/\",\"name\":\"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI=\",\"datePublished\":\"2021-09-02T12:04:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences - Market Newsdesk","og_description":"REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in two upcoming virtual investor conferences in September: H.C. Wainwright 23rd Annual Global Investor Conference: Corporate Presentation available on-demand starting Monday, September 13, 2021 at 7:00 am ET. Citi\u2019s 16th Annual Biopharma Virtual Conference: Management will participate in investor meetings on Thursday, September 9, 2021. A webcast of the H.C. Wainwright 23rd Annual Global Investor Conference presentation may be accessed by visiting the Events &amp; Presentations section of Ayala\u2019s website at ir.ayalapharma.com. An archived replay of the &hellip; Continue reading \"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T12:04:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences","datePublished":"2021-09-02T12:04:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/"},"wordCount":378,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/","name":"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI=","datePublished":"2021-09-02T12:04:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzIyNyM0MzgwODg5IzIxOTUwMTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=533749"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533749\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=533749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=533749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=533749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}